BioMarin

History

Year	Detail
1997	Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery.
2007	BioMarin and IGAN Biosciences collaborated on developing an enzyme therapy to treat IgA Nephropathy, a rare and life-threatening kidney disease.
2010	To expand its core business portfolio, the company acquired ZyStor Therapeutics Inc., a privately held biotechnology company developing enzyme replacement therapies (ERT) for treating lysosomal storage disorders.
2011	The company acquired a bulk biologics manufacturing plant from Pfizer in Shanbally, Cork, Ireland, for $48.5 million to manufacture GALNS products.
2020	BioMarin and Deep Genomics collaborated to use Deep Genomics' artificial intelligence drug discovery platform (The AI Workbench) to identify oligonucleotide drug candidates in four rare disease indications.
2021	The company collaborated with Skyline Therapeutics, a gene and cell therapy company focused on developing novel treatments to discover, develop, and commercialize Adeno-associated virus (AAV) gene therapies to treat genetic cardiovascular diseases.